Dr Naeem Khan PhD

Department of Immunology and Immunotherapy
Senior Research Fellow

Contact details

Telephone
+44 (0)121 414 6785
Email
n.khan.2@bham.ac.uk
Address
Clinical Immunology Services
Department of Immunology and Immunotherapy
Birmingham Medical School (East Wing)
University 麻豆精选
Edgbaston
Birmingham
B15 2TT
UK

Dr Khan is a senior research scientist based in the Department of Immunology and Immunotherapy. He is involved in flow cytometric analysis of leukemia patients enrolled on national acute myeloid leukemia (AML) trials.

Qualifications

  • Fellow of the Higher Education Academy, University of Liverpool
  • PhD in Cancer Studies 2002, University 麻豆精选
  • MSc in Immunology and Immunogenetics, University of Manchester
  • BSc (Hons) in Biochemistry, University of Manchester

Biography

Current research is aimed at advancing our understanding of myeloid cell biology and translating this to improve treatment outcomes for myeloid leukemia patients. Presently, the senior scientist on the AML trials group applying a broad range of modern research skills to dissect differences in the many primitive cell populations in bone marrow from leukaemic patients. Also engaged in collaborations with national and international leukemia clinical research groups.

Teaching

  • MSc Immunology and Immunotherapy – tutorials on haematopoiesis

Postgraduate supervision

Supervising BMedSc student projects:

  • Developing novel flow cytometry assays for predicting chemosensitivity in acute myeloid leukemia patients

Research

  • Acute myeloid leukemia and myelodysplastic /myeloproliferative disorders
  • Developing improved immunophenotyping panels for blood cancers
  • Deep immunophenotyping of immune cells using CyTOF mass cytometry in health and disease
  • Hi-dimensional cytometry data analysis using novel clustering algorithms

Other activities

  • Peer reviewer for a range of journals and funding bodies

Publications

Khan N, Hills RK, Virgo P, Couzens S, Clark N, Gilkes A, Richardson P, Knapper S, Grimwade D, Russell NH, Burnett AK, Freeman SD. (2017) Expression of CD33 is a predictive factor for effect of gemtuzumab ozogamicin at different doses in adult acute myeloid leukaemia. Leukemia. 31(5): 1059-1068 doi: 10.1038/leu.2016.309.

Khan N, Hills RK, Knapper S, Steadman L, Qureshi U, Rector JL, Bradbury C, Russell NH, Vyas P, Burnett AK, Grimwade D, Hole PS and Freeman SD (2016) . PLoS One 11(9):e0163291

Khan N, Hills RK, Virgo P, Couzens S, Clark N, Gilkes A, Grech A, Richardson P, Knapper S, Grimwade D, Russell NH, Burnett AK and Freeman S (2015) . ASH abstract

Halawi M, Khan N and Blake N (2015) . Immun Inflamm Dis 3(2):118-31

Khan N, Freeman SD, Virgo P, Couzens S, Richardson P, Thomas I, Grech A, Vyas P, Grimwade D, Russell NH, Burnett AK and Hills RK (2015) . Br J Haematol 170(1):80-84

Bradbury C, Houlton A, Akiki S, Gregg R, Rindl M, Khan J, Ward J, Khan N, Griffiths M, Nagra S, Hills R, Burnett A, Russell N, Vyas P, Grimwade D, Craddock C and Freeman SD (2015) Leukemia 29(4):988-91

Alejenef A, Pachnio A, Halawi M, Christmas SE, Moss PA and Khan N (2014) . Clin Exp Immunol 176(3):418-28

Almehmadi M, Flanagan BF, Khan N, Alomar S and Christmas SE (2014) . Immunology 142(2):258-68